|
|
 |
|
Viewing report
|
|
|
|
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
Business Insights, Dec 2007, Pages: 195
The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry. With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding activity, conditions appear highly favourable for further growth. ‘Lifestyle Drugs Market Outlook’ is a new report that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management. Key industrial trends in the fields of consumer demand and pipeline development are examined, leading players and products within each treatment area are profiled and the market potential of each lifestyle therapy is assessed. This report will also provide a substantial review of reimbursement policies within the seven major markets and their impact upon product sales.
Some key findings from this report...
-The global oral contraceptive market was worth $4378.7m in 2006, of which US sales accounted for 74.7%. The market leader Yasmin controlled 17% of global sales during this period, with an innovative formulation, positive side-effect profile and extended indication approval helping it to overcome high levels of competition.
-The European and US markets for skincare had a combined value of $6590m in 2006, and are projected to reach $8486m by 2011.
-Pfizer’s Champix controlled over 50% of global revenues for smoking cessation therapies by Q2 2007, despite a 2006 launch. This rapid success has been attributed to the drug’s novel formulation, high compliancy, proven efficacy and successful promotional launch.
-The worldwide erectile dysfunction market was worth $3203.6m in 2006, with Pfizer’s Viagra commanding a share of over 50%. Viagra sales have been falling since 2003 and will continue declining until patent expiry in 2013, however direct competition from PDE-5 inhibitors is unlikely due to Viagra’s strong brand and patent strength.
-Anti-ageing products comprise the fastest growing sector of the worldwide cosmeceutical market. Skincare products lead the market, accounting for 80% of total US and European cosmeceutical sales.
Top five reasons to order your copy today
-Assess the market potential of key lifestyle therapies with this report’s detailed analysis of demand and epidemiology for conditions such as Alcohol Dependence, Alopecia, Obesity, Oral Contraception Sexual Dysfunction, Skin Aging and Smoking Cessation.
-Understand the major issues affecting lifestyle drug revenues across global markets with this report’s examination of consumer spend dynamics and current pricing and reimbursement environments in countries including Japan, France, Germany, Italy, Spain, Canada, Australia, China, the US and the UK.
-Identify key success factors within the lifestyle drugs market by benchmarking the successful growth strategies of leading drug developers and technological innovators.
-Anticipate future trends and scenarios with in-depth analysis of the main drivers and resistors to market growth in addition to the latest innovations in lifestyle drug development, dosing and delivery.
-Evaluate the best methods of obtaining reimbursement and recognition for lifestyle drugs with this report’s comprehensive review of strategic options across the seven major markets.
Key issues examined in this report...
-Reimbursement. Healthcare providers are under mounting pressure to provide patient reimbursement for the cost of lifestyle drugs, particularly for anti-obesity and smoking cessation therapies. The increasingly prohibitive costs of reimbursement for related conditions have triggered the proposed policy changes.
-Disease classification. As lifestyle conditions increasingly become recognized as treatable diagnoses, the clarification of diagnostic criterion is accelerating the development of targeted treatments
-Demographics. Aging populations and rising disposable incomes in developed countries are expected to have a positive impact on lifestyle therapy revenues as consumers become more informed and financially able to treat symptoms associated with lifestyle diseases.
-Chronic therapy use. With many lifestyle conditions requiring long-term therapy commitments for optimal results, organizations are striving to develop safer and more affordable drugs that can improve levels of patient compliance.
Your questions answered...
-How are lifestyle conditions defined, recognized, measured and diagnosed by physicians?
-What are the key issues currently influencing consumer demand?
-Which strategies can extend patent protection and maximize revenue potential most effectively?
-What are the major current pricing and reimbursement issues prevalent within the seven major markets?
-Which strategies can successfully secure reimbursement approval?
-What are the most promising pipeline therapies currently in development?
-To what extent will new therapies impact the lifestyle drugs market?
-How will patent expirations impact pricing, competition and brand revenues across the seven major markets?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
The Lifestyle Drugs Outlook To 2008: Unlocking New Value In Well-Being
Obesity Drug Pipeline: Developing Therapies for a Complex Disease
U.S. Sexual Dysfunction Medication Markets
The Lifestyle Drugs Outlook To 2007: Challenges And Opportunities In A High-Profile Growth Market
U.S. Smoking Cessation Drug Market
Erectile Dysfunction Therapy Area Pipeline Report
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Female Sexual Dysfunction Therapy Area Pipeline Report
Booming Global Obesity Drug Market
Valuing Pharmaceutical Innovation: Pricing and Reimbursement for Innovative Therapies
Alopecia (Hair Loss) Therapy Area Pipeline Report
|
|
|
|
